Thymosin alpha 1 and HIV-1: Recent advances and future perspectives

Future Microbiology

Volumn 12, Issue 2, 2017, Pages 141-155

  Matteucci, Claudia ^a   Grelli, Sandro ^a   Balestrieri, Emanuela ^a   Minutolo, Antonella ^a   Argaw Denboba, Ayele ^a   Macchi, Beatrice ^a   Sinibaldi Vallebona, Paola ^a,b   Perno, Carlo Federico ^a   Mastino, Antonio ^b,c   Garaci, Enrico ^a,d  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

ART; CD8 antiviral factor; HIV; immune dysfunction; immune reconstitution

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; THYMOSIN ALPHA1; THYMOSIN;

ANTIRETROVIRAL THERAPY; CD8+ T LYMPHOCYTE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; LYMPHOID CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLEIOTROPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THYMUS; TRANSCRIPTION REGULATION; VACCINATION; ANALOGS AND DERIVATIVES; CYTOLOGY; DRUG EFFECTS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; LYMPHOCYTE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THYMOSIN;

EID: 85011263052     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb-2016-0125     Document Type: Review

References (103)

1. Sarandeses CS, Covelo G, Díaz-Jullien C, Freire M. Prothymosin alpha is processed to thymosin alpha 1 and thymosin alpha 11 by a lysosomal asparaginyl endopeptidase. J. Biol. Chem. 278(15), 13286-13293 (2003).
2. Goldstein AL, Low TL, McAdoo M, et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc. Natl Acad. Sci. USA 74(2), 725-729 (1977).
3. Low TL, Thurman GB, McAdoo M, et al. The chemistry and biology of thymosin. Isolation, characterization, and biological activities of thymosin alpha1 and polypeptide beta1 from calf thymus. J. Biol. Chem. 254(3), 981-986 (1979).
4. Garaci E, Favalli C, Pica F, et al. Thymosin alpha 1: from bench to bedside. Ann. N. Y. Acad. Sci. 1112, 225-234 (2007).
5. Matteucci C, Minutolo A, Sinibaldi-Vallebona P, et al. Transcription profile of human lymphocytes following in vitro treatment with thymosin alpha-1. Ann. N. Y. Acad. Sci. 1194, 6-19 (2010).
6. Serafino A, Pierimarchi P, Pica F, et al. Thymosin a1 as a stimulatory agent of innate cell-mediated immune response. Ann. N. Y. Acad. Sci. 1270, 13-20 (2013).
7. Knutsen AP, Freeman JJ, Mueller KR, Roodman ST, Bouhasin JD. Thymosinalpha1 stimulates maturation of CD34+ stem cells into CD3+4+ cells in an in vitro thymic epithelia organ coculture model. Int. J. Immunopharmacol. 21(1), 15-26 1999).
8. Sztein MB, Serrate SA, Goldstein AL. Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones. Proc. Natl Acad. Sci. USA 83(16), 6107-6111 (1986).
9. Oates KK, Sztein MB, Goldstein AL. Mechanism of action of the thymosins: modulation of lymphokines, receptors, and T-cell differentiation antigens. Immunol. Ser 45, 273-288 (1989).
10. Giuliani C, Napoletano G, Mastino A, et al. Thymosin-Alpha1 regulates MHC class I expression in FRTL-5 cells at transcriptional level. Eur. J. Immunol. 30(3), 778-786 2000).
11. Garaci E, Pica F, Serafino A, et al. Thymosin a1 and cancer: action on immune effector and tumor target cells. Ann. N. Y. Acad. Sci. USA 1269, 26-33 (2012).
12. Favalli C, Jezzi T, Mastino A, et al. Modulation of natural killer activity by thymosin alpha 1 and interferon. Cancer Immunol. Immunother. 20(3), 189-192 1985).
13. Garaci E, Pica F, Sinibaldi-Vallebona P, et al. Thymosin alpha(1) in combination with cytokines and chemotherapy for the treatment of cancer. Int. Immunopharmacol. 3(8), 1145-1150 (2003).
14. Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 103(11), 4232-4239 2004).
15. Bozza S, Gaziano R, Bonifazi P, et al. Thymosin alpha1 activates the TLR9/ MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo. Int. Immunol. 19(11), 1261-1270 (2007).
16. Romani L, Moretti S, Fallarino F, et al. Jack of all trades: thymosin a1 and its pleiotropy. Ann. N. Y. Acad. Sci. 1269, 1-6 (2012).
17. Serafino A, Pica F, Andreola F, et al. Thymosin a1 activates complement receptor-mediated phagocytosis in human monocyte-derived macrophages. J. Innate Immun. 6(1), 72-88 (2014).
18. Nepravishta R, Mandaliti W, Eliseo T, et al. Thymosin a1 inserts N terminus into model membranes assuming a helical conformation. Expert Opin. Biol. Ther. 15(Suppl. l), 71-81 2015).
19. Mandaliti W, Nepravishta R, Sinibaldi Vallebona P, et al. New studies about the insertion mechanism of Thymosin a1 in negative regions of model membranes as starting point of the bioactivity. Amino Acids 48(5), 1231-1239 (2016).
20. Mandaliti W, Nepravishta R, Sinibaldi Vallebona P, et al. Thymosin a1 interacts with exposed phosphatidylserine in membrane models and in cells and uses serum albumin as a carrier. Biochemistry 55(10), 1462-1472 2016).
21. Matteucci C, Minutolo A, Pollicita M, et al. Thymosin a 1 potentiates the release by CD8(+) cells of soluble factors able to inhibit HIV-1 and human T lymphotropic virus 1 infection in vitro. Expert Opin. Biol. Ther. 15(Suppl. 1), 83-100 (2015).
22. Naylor PH, Quadrini K, Garaci E, Rasi G, Hadden JW. Immunopharmacology of thymosin alpha1 and cytokine synergy. Ann. N. Y. Acad. Sci. 1112, 235-244 (2007).
23. Camerini R, Garaci E. Historical review of thymosin a 1 in infectious diseases. Expert Opin. Biol. Ther. 15(Suppl. 1), 117-127 2015).
24. Garaci E, Pica F, Matteucci C, et al. Historicalreview on thymosin a1 in oncology: preclinical and clinicalexperiences. Expert Opin. Biol. Ther. 15(Suppl. 1), 31-39 (2015).
25. Favalli C, Mastino A, Jezzi T, Grelli S, Goldstein AL, Garaci E. Synergistic effect of thymosin alpha 1 and alpha beta-interferon on NK activity in tumor-bearing mice. Int. J. Immunopharmacol. 11(5), 443-450 (1989).
26. Mastino A, Favalli C, Grelli S, Innocenti F, Garaci E. Thymosin alpha 1 potentiates interleukin 2-induced cytotoxic activity in mice. Cell Immunol. 133(1), 196-205 (1991).
27. D'Agostini C, Palamara AT, Favalli C, et al. Efficacy of combination therapy with amantadine, thymosin alpha 1 and alpha/beta interferon in mice infected with influenza A virus. Int. J. Immunopharmacol. 18(2), 95-102 (1996).
28. Mastino A, Favalli C, Grelli S, et al. Combination therapy with thymosin alpha 1 potentiates the anti-Tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice. Int. J. Cancer 50(3), 493-499 (1992).
29. Pica F, Fraschetti M, Matteucci C, et al. High doses of thymosin alpha 1 enhance the anti-Tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma. Anticancer Res. 18(5A), 3571-3578 (1998).
30. Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin. Biol. Ther. 9(5), 593-608 (2009).
31. Perruccio K, Bonifazi P, Topini F, et al. Thymosin alpha1 to harness immunity to pathogens after haploidentical hematopoietic transplantation. Ann. N. Y. Acad. Sci. 1194, 153-161 (2010).
32. Tuthill CW, King RS. Thymosin apha 1-A peptide immune modulator with a broad range of clinical applications. Clin. Exp. Pharmacol. 3(4), 133 (2013).
33. Liu F, Wang HM, Wang T, Zhang YM, Zhu X. The efficacy of thymosin a1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials. BMC Infect. Dis. 16(488), 1-12 (2016).
34. Ershler WB, Gravenstein S, Geloo ZS. Thymosin alpha 1 as an adjunct to influenza vaccination in the elderly: rationale and trial summaries. Ann. N. Y. Acad. Sci. 1112, 375-384 (2007).
35. Tuthill C, Rios I, De Rosa A, Camerini R. Thymosin a1 continues to show promise as an enhancer for vaccine response. Ann. N. Y. Acad. Sci. 1270(1), 21-27 (2012).
36. Pica F, Chimenti MS, Gaziano R, Buè C, et al. Serum thymosin a 1 levels in patients with chronic inflammatory autoimmune diseases. Clin. Exp. Immunol. 186(1), 39-45 (2016).
37. Okoye AA, Picker LJ. CD4+ T-cell depletion in HIV infection: mechanisms of immunological failure. Immunol. Rev. 254(1), 54-64 (2013).
38. Williams KC, Burdo TH. HIV and SIV infection: the role of cellular restriction and immune responses in viral replication and pathogenesis. APMIS 117 (5-6), 400-412 2009).
39. Fanales-Belasio E, Raimondo M, Suligoi B, Butto S. HIV virology and pathogenetic mechanisms of infection: a brief overview. Ann. Ist. Super. Sanita. 46(1), 5-14 (2010).
40. Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 37(3), 377-388 (2012).
41. Van Lint C, Bouchat S, Marcello A. HIV-1 transcription and latency: an update. Retrovirology 10(1), 67 (2013).
42. Archin NM, Sung JM, Garrido C, Soriano-Sarabia N, Margolis DM. Eradicating HIV-1 in fection: seeking to clear a persistent pathogen. Nat. Rev. Microbiol. 12(11), 750-764 (2014).
43. Levy JA. Virus-host interactions in HIV pathogenesis directions for therapy. Adv. Dent. Res. 23(1), 13-18 (2011).
44. AIDSinfo. HIV treatment FDA-Approved HIV medicines (2016). https://aidsinfo.nih.gov/
45. European Medicine Agency. Authorised medicine for HIV infections. European public assessment reports (2016). ema.europa.eu/ema/
46. Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. Cold Spring Harb. Perspect. Med. 2(4), a007161 (2012).
47. Margolis AM, Heverling H, Pham PA, Stolbach A. A review of the toxicity of HIV medications. J. Med. Toxicol. 10(1), 26-39 2014).
48. Palmisano L, Vella S. A brief history of antiretroviral therapy of HIV infection: success and challenges. Ann. Ist. Super. Sanita. 47(1), 44-48 (2011).
49. Sandler NG, Sereti I. Can ART treatment reduce long-Term complications by reducing inflammation? Curr. Opin. HIV AIDS 9(1), 72-79 (2014).
50. Corbeau P, Reynes J. Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection. Blood 117(21), 5582-5590 (2011).
51. Gaardbo JC, Hartling HJ, Gerstoft J, Nielsen SD. Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin. Dev. Immunol. 2012, 670957 (2012).
52. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu. Rev. Med. 62, 141-155 (2011).
53. Wilson EM, Sereti I. Immune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs. Immunol. Rev. 254(1), 343-354 (2013).
54. Paiardini M, Müller-Trutwin M. HIVassociated chronic immune activation. Immunol. Rev. 254(1), 78-101 (2013).
55. Reuter MA, Pombo C, Betts MR. Cytokine production and dysregulation in HIV pathogenesis: lessons for development of therapeutics and vaccines. Cytokine Growth Factor Rev. 23(4), 181-191 (2012).
56. Keating SM, Jacobs ES, Norris PJ. Soluble mediators of inflammation in HIV and their implications for therapeutics and vaccine development. Cytokine Growth Factor Rev. 23(4), 193-206 (2012).
57. Wilson EM, Singh A, Hullsiek KH, et al. Monocyte-Activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection. J. Infect. Dis. 210(9), 1396-1406 (2014).
58. Aberg JA. Aging, inflammation, and HIV infection. Top. Antivir. Med. 20(3), 101-105 2012).
59. Lichtfuss GF, Cheng WJ, Farsakoglu Y, et al. Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation. J. Immunol. 189(3), 1491-1499 (2012).
60. Downey JS, Imami N. T-cell dysfunction in HIV-1 infection: targeting the inhibitors. HIV Ther. 4(1), 83-99 (2010).
61. Marchetti G, Tincati C, Silvestri G. Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin. Microbiol. Rev. 26(1), 2-18 (2013).
62. Utay NS, Ananworanich J, Pinyakorn S, et al. Inflammation persists despite early initiation of ART in acute HIV infection. Presented at: 22nd Conference on Retroviruses and Opportunistic Infections. Seattle, Washington DC, USA, 23-26 February 2015.
63. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin. Infect. Dis. 42(3), 418-427 2006).
64. Bosamiya SS. The immune reconstitution inflammatory syndrome. Indian J. Dermatol. 56(5), 476-479 (2011).
65. French MA. Immune reconstitution inflammatory syndrome: a reappraisal. Clin. Infect. Dis. 48(1), 101-107 (2009).
66. Boulougoura A, Sereti I. HIV infection and immune activation: the role of coinfections. Curr. Opin. HIV AIDS. 11(2), 191-200 2016).
67. Morrow MP, Weiner DB. Cytokines as adjuvants for improving anti-HIV responses. AIDS. 22(3), 333-338 (2008).
68. Sabbatini F, Bandera A, Ferrario G, et al. Qualitative immune modulation by interleukin-2 (IL-2) adjuvant therapy in immunological non responder HIV-infected patients. PLoS ONE 29(11), e14119 (2010).
69. Noto A, Trautmann L. Developing combined HIV vaccine strategies for a functional cure. Vaccines 1(4), 481-496 (2013).
70. Pappas PG, Bustamante B, Ticona E, et al. Recombinant interferon-gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J. Infect. Dis. 189(12), 2185-2191 (2004).
71. Garaci E, Rocchi G, Perroni L, et al. Combination treatment with zidovudine, thymosin alpha 1 and interferon-Alpha in human immunodeficiency virus infection. Int. J. Clin. Lab. Res. 24(1), 23-28 (1994).
72. Ramachandran R, Katzenstein DA, Winters MA, Kundu SK, Merigan TC. Polyethylene glycol-modified interleukin-2 and thymosin alpha 1 in human immunodeficiency virus type 1 infection. J. Infect. Dis. 173(4), 1005-1008 (1996).
73. Garaci E, Milanese G, Vella S, et al. A randomized controlled study for the evaluation of the activity of a triple combination of zidovudine, thymosin alpha 1 and interferon alpha in HIV-infected individuals with CD4 counts between 200 and 500 cells/mm3. Antiviral Ther. 3, 103-111 (1998).
74. Chadwick D, Pido-Lopez J, Pires A, et al. A pilot study of the safety and efficacy of thymosin alpha 1 in augmenting immune reconstitution in HIV-infected patients with low CD4 counts taking highly active antiretroviral therapy. Clin. Exp. Immunol. 134(3), 477-481 (2003).
75. Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature 334(6181), 395-402 (1988).
76. Hazenberg MD, Verschuren MC, Hamann D, Miedema F, van Dongen JJ. T cell receptor excision circles as markers for recent thymic emigrants: basic aspects, technical approach, and guidelines for interpretation. J. Mol. Med. 79(11), 631-640 (2001).
77. Spits H. Development of alphabeta T cells in the human thymus. Nat. Rev. Immunol. 2(10), 760-772 (2002).
78. Ho Tsong Fang R, Colantonio AD, Uittenbogaart CH. The role of the thymus in HIV infection: a 10 year perspective. AIDS 22(2), 171-184 (2008).
79. Somech R. T-cell receptor excision circles in primary immunodeficiencies and other T-cell immune disorders. Curr. Opin. Allergy Clin. Immunol. 11(6), 517-524 (2011).
80. Mackall CL, Fleisher TA, Brown MR, et al. Age, Thymopoiesis, and CD4+ T lymphocyte regeneration after intensive chemotherapy. N. Engl. J. Med. 332, 143-149 (1995).
81. Haynes BF, Markert ML, Sempowski GD, Patel DD, Hale LP. The role of the thymus in immune reconstitution in aging, bone-marrow transplantation and HIV-1 infection. Annu. Rev. Immunol. 18, 529-560 2000).
82. Williams KM, Gress RE. Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation. Best. Pract. Res. Clin. Haematol. 21(3), 579-596 (2008).
83. Baumann CA, Badamchian M, Goldstein AL. Thymosin alpha 1 antagonizes dexamethasone and CD3-induced apoptosis of CD4+ CD8+ thymocytes through the activation of cAMP and protein kinase C dependent second messenger pathways. Mech. Ageing Dev. 94(1-3), 85-101 (1997).
84. Nunes-Alves C, Nobrega C, Behar SM, Correia-Neves M. Tolerance has its limits: how the thymus copes with infection. Trends Immunol. 34(10), 502-510 (2013).
85. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 396(6712), 690-695 (1998).
86. Dion ML, Poulin JF, Bordi R, et al. HIV infection rapidly induces and maintains a substantial suppression of thymocyte proliferation. Immunity 21 (6), 757-768 2004).
87. Bandera A, Ferrario G, Saresella M, et al. CD4+ T cell depletion, immune activation and increased production of regulatory T cells in the thymus of HIV-infected individuals. PLoS ONE 24(5), e10788 (2010).
88. Sasson SC, Zaunders JJ, Seddiki N, et al. Progressive activation of CD127+132-recent thymic emigrants into terminally differentiated CD127-132+ T-cells in HIV-1 infection. PLoS ONE 7(2), e31148 (2012).
89. Hatzakis A, Touloumi G, Karanicolas R, et al. Effect of recent thymic emigrants on progression of HIV-1 disease. Lancet 355 9204), 599-604 (2000).
90. Pido-Lopez J, Pires A, Nelson M, et al. Thymic activity in late-stage HIV-1 infected individuals receiving highly active antiretroviral therapy: potential effect of steroid therapy. HIV Med. 3(1), 56-61 2002).
91. Franco JM, Rubio A, Martínez-Moya M, et al. T-cell repopulation and thymic volume in HIV-1-infected adult patients after highly active antiretroviral therapy. Blood 99(10), 3702-3706 (2002).
92. Sandgaard KS, Lewis J, Adams S, Klein N, Callard R. Antiretroviral therapy increases thymic output in children with HIV. AIDS 28(2), 209-214 (2014).
93. Jiménez VC, Wit FW, Joerink M, et al. T-Cell activation independently associates with immune senescence in HIV-infected recipients of long-Term antiretroviral treatment. J. Infect. Dis. 214(2), 216-225 (2016).
94. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17, 657-700 (1999).
95. Pal R, Garzino-Demo A, Markham PD, et al. Inhibition of HIV-1 infection by the beta-chemokine MDC. Science 278(5338), 695-698 (1997).
96. Matloubian M, David A, Engel S, Ryan JE, Cyster JG. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat. Immunol. 1(4), 298-304 (2000).
97. Walker CM, Moody DJ, Stites DP, Levy JA. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234(4783), 1563-1566 (1986).
98. Saksena NK, Wu JQ, Potter SJ, Wilkinson J, Wang B. Human immunodeficiency virus interactions with CD8+ T lymphocytes. Curr. HIV Res. 6(1), 1-9 (2008).
99. DeVico AL, Gallo RC. Control of HIV-1 infection by soluble factors of the immune response. Nat. Rev. Microbiol. 2, 401-413 2004).
100. Müller H, Mayer G, Behnke B, et al. Enhancing of anti-viral activity against HIV-1 by stimulation of CD8+ T cells with thymic peptides. Clin. Exp. Immunol. 117(1), 76-83 (1999).
101. Saunders KO, Ward-Caviness C, Schutte RJ, et al. Secretion of MIP-1b and MIP-1a by CD8(+) T-lymphocytes correlates with HIV-1 inhibition independent of coreceptor usage. Cell Immunol. 266(2), 154-164 (2011).
102. Lambert JS, Machado ES, Watson DC, et al. Production of the HIV-suppressive chemokines CCL3/MIP-1alpha and CCL22/ MDC is associated with more effective antiretroviral therapy in HIV-infected children. Pediatr. Infect. Dis. J. 26(10), 935-944 (2007).
103. Payne TL, Blackinton J, Frisbee A, et al. Transcriptional and posttranscriptional regulation of cytokine gene expression in HIV-1 antigen-specific CD8+ T cells that mediate virus inhibition. J. Virol. 88(17), 9514-9528 (2014).